Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]

  • In development
  • GID-TA10780
  • Expected publication date: TBC

Topic is suspended

Status:
Suspended
Decision:
Prioritised
Process:
TA
ID number:
3861

Timeline

Key events during the development of the guidance:

Date Update
08 January 2021 Note added to the project documents
08 January 2021 Suspended. Topic is suspended

For further information on our processes and methods, please see our CHTE processes and methods manual